

# Nationwide Monitoring for *Plasmodium falciparum* Drug-Resistance Alleles to Chloroquine, Sulfadoxine, and Pyrimethamine, Haiti, 2016–2017

## Appendix

**Appendix Table 1.** Primers and PCR conditions for *Pfcrt*, *Pfdhfr*, and *Pfdhps* amplification\*

Gene target	Primer (5'→3')	Thermocycling conditions†
<i>Pfcrt</i>		
Primary rxn		94°/5 min; [95°/30 sec; 56°/30 sec; 65°/1 min] ×30 ; 65°/5 min
Forward	CATTGTCTTCCACATATATGACATAAA	
Reverse	TTGGTAGGTGGAATAGATTCTCTT	
secondary rxn		94°/5 min; [95°/30 sec; 60°/30 sec; 65°/1 min] ×30 ; 65°/5 min
Forward	CCGTTAATAATAAACACCGCAG	
Reverse	AATTCCTCCTTTTATTCCTAAATAAGG	
Sequencing rxn	AATTCCTCCTTTTATTCCTAAATAAGG	96°/1 min; [96°/10 sec; 50°/5 sec; 60°/4 min] ×25
<i>Pfdhfr</i>		
Primary rxn		95°/5 min; [95°/30 sec; 50°/30 sec; 68°/1 min] ×30; 68°/5 min
Forward	TCCTTTTTATGATGGAACAAG	
Reverse	AGTATATACATCGCTAACAGA	
secondary rxn		95°/5 min; [95°/30 sec; 52°/30 sec; 68°/1 min] ×30; 68°/5 min
Forward	TTTATGATGGAACAAGTCTGC	
Reverse	ACTCATTTCATTTATTTCTGG	
Sequencing rxn	TTTATGATGGAACAAGTCTGC	96°/1 min; [96°/10 sec; 50°/5 sec; 60°/4 min] ×25
<i>Pfdhps</i>		
PCR rxn		95°/5 min; [95°/30 sec; 53°/30 sec; 68°/1 min] ×40; 68°/5 min
Forward	AACCTAAACGTGCTGTTCAA	
Reverse	TCATTTGTTGTTCATCATGT	
Sequencing rxn		96°/1 min; [96°/10 sec; 50°/5 sec; 60°/4 min] ×25
Forward	CTATAGTGTAGTTCTAATGC	
Reverse	CAACTAAATCATTATCACACATTC	

\*rxn, reaction.

†Initialization; [denaturation; annealing; extension] x cycles; final elongation


**Appendix Table 2.** Number of samples successfully sequenced (and as percentage of total samples selected from that site) for reporting of putative drug resistance codons for genes *Pfcrt*, *Pfdhfr*, *Pfdhps*, by participating healthcare facility, Haiti 2016–2017\*

Site (no. samples)	<i>Pfcrt</i>				<i>Pfdhfr</i>					<i>Pfdhps</i>				
	C72S	M74I	N75E	K76T	C50R	N51I	C59R	S108N	I164L	S436X†	A437G	K540E	A581G	A613X‡
Arnaud (211)	208 (99)	208 (99)	208 (99)	208 (99)	135 (64)	135 (64)	135 (64)	135 (64)	135 (64)	155 (73)	155 (73)	129 (61)	141 (67)	135 (64)
Capotille (13)	11 (92) (92)	11 (92)	11 (92)	11 (92)	9 (75)	9 (75)	9 (75)	9 (75)	9 (75)	6 (50)	6 (50)	6 (50)	5 (42)	4 (33)
Cazale (23)	23 (100)	23 (100)	23 (100)	23 (100)	16 (70)	16 (70)	16 (70)	15 (65)	15 (65)	8 (35)	8 (35)	7 (30)	7 (30)	8 (35)
Dalphane (21)	21 (100)	21 (100)	21 (100)	21 (100)	19 (90)	19 (90)	19 (90)	18 (86)	19 (90)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Lavanneau (12)	12 (100)	12 (100)	12 (100)	12 (100)	4 (33)	4 (33)	4 (33)	6 (50)	4 (33)	1 (8)	1 (8)	1 (8)	1 (8)	1 (8)
Les Anglais (211)	195 (92)	195 (92)	195 (92)	195 (92)	152 (72)	152 (72)	152 (72)	152 (72)	152 (72)	138 (65)	138 (65)	123 (58)	141 (67)	140 (66)
Pignon (2)	2 (100)	2 (100)	2 (100)	2 (100)	2 (100) (100)	2 (100)	2 (100)	2 (100)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Roseaux (68)	62 (94)	62 (94)	62 (94)	62 (94)	48 (71)	48 (71)	48 (71)	47 (69)	48 (71)	39 (57)	39 (57)	24 (35)	34 (50)	32 (47)
Sainte-Hélène (199)	190 (95) (95)	190 (95)	190 (95)	190 (95)	150 (75)	150 (75)	150 (75)	149 (75)	150 (75)	138 (69)	138 (69)	116 (58)	136 (68)	138 (69)
Thomonde (18)	17 (94)	17 (94)	17 (94)	17 (94)	16 (89)	16 (89)	16 (89)	15 (83)	15 (83)	3 (17)	3 (17)	0 (0)	0 (0)	0 (0)
Total (778)	741 (95)	741 (95)	741 (95)	741 (95)	551 (71)	551 (71)	551 (71)	548 (71)	549 (70)	488 (71)	488 (63)	406 (63)	465 (52)	458 (60)

\*Values are no. (%) unless indicated.

†S436A, S436Y, or S436F mutations.

‡A613S or A613T mutations.



**Appendix Figure.** Concordance of PET-PCR cycle threshold (C<sub>t</sub>) values from first 325 samples in drug resistance survey, Haiti 2016. Scatterplot of C<sub>t</sub> values for PET-PCR reactions as run at the Haitian National Laboratory versus the same person's sample with DNA extraction and PET-PCR assay at CDC in Atlanta, Georgia.